Befunolol

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 12:54, 27 June 2015 (Infobox drug: rm/replace dedeprecated params. Fix unk parameters (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 413883923 | IUPAC_name = (RS)-1-{7-[2-hydroxy-3-(propan-2-ylamino)propoxy]- 1-benzofuran-2-yl}ethanone | image = Befunolol.svg | tradename = Benfuran, Bentos, Betaclar, Glauconex | Drugs.com = International Drug Names | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref =  checkY | CAS_number = 39552-01-7 | ATC_prefix = S01 | ATC_suffix = ED06 | PubChem = 2309 | DrugBank_Ref =  ☒N | DrugBank = DB09013 | ChemSpiderID_Ref =  checkY | ChemSpiderID = 2219 | UNII_Ref =  checkY | UNII = 418546MT3A | KEGG_Ref =  checkY | KEGG = D07496 | ChEMBL_Ref =  checkY | ChEMBL = 153984 | C=16 | H=21 | N=1 | O=4 | molecular_weight = 291.342 g/mol | smiles = O=C(c2oc1c(OCC(O)CNC(C)C)cccc1c2)C | InChI = 1/C16H21NO4/c1-10(2)17-8-13(19)9-20-14-6-4-5-12-7-15(11(3)18)21-16(12)14/h4-7,10,13,17,19H,8-9H2,1-3H3 | InChIKey = ZPQPDBIHYCBNIG-UHFFFAOYAP | StdInChI_Ref =  checkY | StdInChI = 1S/C16H21NO4/c1-10(2)17-8-13(19)9-20-14-6-4-5-12-7-15(11(3)18)21-16(12)14/h4-7,10,13,17,19H,8-9H2,1-3H3 | StdInChIKey_Ref =  checkY | StdInChIKey = ZPQPDBIHYCBNIG-UHFFFAOYSA-N }} Befunolol (INN) is a beta blocker with intrinsic sympathomimetic activity used in the management of open-angle glaucoma.[1]

References

  1. ^ Stephan Reichl, Christel C Müller-Goymann (2 January 2003). "The use of a porcine organotypic cornea construct for permeation studies from formulations containing befunolol hydrochloride". International Journal of Pharmaceutics. 250 (1): 191–201. doi:10.1016/S0378-5173(02)00541-0.